The global diabetes devices market was valued at USD 32.4 billion in 2024 and is projected to reach USD 70.6 billion by the end of 2035, growing at a CAGR of 7.4% from 2025 to 2035. Growth is driven by the rising global prevalence of diabetes, increasing adoption of continuous glucose monitoring (CGM) systems and insulin delivery devices, and growing awareness of self-management technologies. Technological advancements and expanding healthcare access in emerging markets are further supporting strong industry expansion over the forecast period.

Technological advancements are visibly improving diabetes devices’ performance. Connecting devices with intelligent technology, for instance mobile health apps and telehealth platforms, facilitate real-time information exchange between patients and clinicians, thereby making it possible to provide more personalized treatment regimens.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

Research is being conducted on automated insulin treatment systems, otherwise known as "artificial pancreas" technology, which is transforming the management of diabetes by reducing patients' burden.

Key Findings of the Market Report

• Glucose Monitoring Devices dominated the product segment in 2025, with CGM sensors alone accounting for over 56% of the monitoring market as real-time tracking becomes the clinical standard.
• Type 2 Diabetes remains the largest application segment, representing nearly two-thirds (66%) of the global market due to rising obesity rates and sedentary lifestyles.
• Insulin Delivery Devices are projected to be the fastest-growing sub-segment, driven by the adoption of smart insulin pens and tubeless patch pumps.
• North America held the leading regional share of 38.7% in 2025, while Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 14.4% due to improving healthcare access in China and India.

Global Diabetes Devices Market: Growth Drivers

• Shift to Continuous Monitoring: The move away from episodic blood glucose monitoring (BGM) toward 10-day and 15-day CGM sensors has revolutionized patient adherence and glycemic control.
• Automated Insulin Delivery (AID): The rise of "Artificial Pancreas" systems—which integrate CGMs with insulin pumps via AI algorithms—is significantly reducing the burden of manual dosing for Type 1 patients.
• Over-the-Counter (OTC) Expansion: In 2024-2025, the launch of OTC CGMs (like Dexcom’s Stelo) for non-insulin-using Type 2 diabetics opened a massive new consumer health segment.
• Integration with Digital Health: The convergence of device data with mobile apps and cloud-based platforms allows for real-time remote monitoring by healthcare providers and personalized AI insights for patients.

Global Diabetes Devices Market: Regional Landscape

• North America: Leading the market in value, driven by high per-capita healthcare spending and favorable reimbursement for advanced "Closed-Loop" systems.
• Asia-Pacific: Home to the world's largest diabetic population. Market growth is accelerated by government initiatives like India's PLI scheme for local medical device manufacturing.
• Europe: Focuses on the integration of digital health apps with public health registries and the rapid adoption of Bio-LNG-equivalent sustainability in device disposal.

Global Diabetes Devices Market: Key Players

The market is highly consolidated, with "The Big Three" (Abbott, Dexcom, and Medtronic) leading the charge in visualization and delivery technology.

• Abbott Laboratories (Leader in CGM with the FreeStyle Libre brand)
• Dexcom, Inc. (Pioneer in high-accuracy real-time CGM systems)
• Medtronic plc (Leader in integrated insulin pumps and AID systems)
• F. Hoffmann-La Roche Ltd. (Strong presence in BGM and digital health)
• Insulet Corporation (Market leader in tubeless patch pumps)
• Tandem Diabetes Care, Inc.
• Ascensia Diabetes Care
• Becton, Dickinson and Company (BD)
• Novo Nordisk A/S
• Sanofi

Key Developments (2025–2026)

• April 2025: Dexcom received FDA clearance for the G7 15-Day sensor, extending the wear time from the previous 10-day limit.
• March 2025: Tandem Diabetes Care launched Control-IQ+, an advanced hybrid closed-loop algorithm compatible with both the t:slim X2 and the Tandem Mobi system.
• July 2025: Medtronic received CE Mark in Europe to expand the use of its MiniMed 780G system for pregnant women and Type 2 insulin-requiring patients.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=14&ltype=S

Global Diabetes Devices Market: Segmentation

By Product Type

• Monitoring Devices: Self-Monitoring (Meters, Strips), Continuous Glucose Monitors (Sensors, Transmitters).
• Management/Delivery Devices: Insulin Pumps (Tethered, Patch), Insulin Pens (Smart, Disposable), Syringes.

By Disease Type

• Type 1 Diabetes
• Type 2 Diabetes (Largest Share)
• Gestational Diabetes

By End-User

• Home Care Settings (Fastest Growing)
• Hospitals & Specialty Clinics
• Diagnostic Centers

By Distribution Channel

• Retail Pharmacies
• Online Pharmacies (Rising Growth)
• Hospital Pharmacies

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: sales@transparencymarketresearch.com